Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Mamoudou Maiga, Shichun Lun, Haidan Guo, Kathryn Winglee, Nicole C. Ammerman, William R. Bishai

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

Original languageEnglish (US)
Pages (from-to)1705-1708
Number of pages4
JournalJournal of Infectious Diseases
Issue number11
StatePublished - Jun 1 2012

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Risk of tuberculosis reactivation with tofacitinib (CP-690550)'. Together they form a unique fingerprint.

Cite this